21/04/2017 12:20:00

Participate in our $3 million Private Placement to Earn a Potential 20% Return on Investment in THC Therapeutics (THCT) Stock

LAS VEGAS, April 21, 2017 (GLOBE NEWSWIRE) -- THC Therapeutics (THCT) is offering a Reg D private placement to accredited investors, through which we will raise up to $3,000,000. Proceeds from this offering will start the process for THC Therapeutics to become a fully reporting company to the SEC. 50% of the money raised will go towards mergers and acquisitions, the other half will go toward general business operating expenses. This offering will be good for our company, current shareholders and new investors. An example of the terms is as follows, for a $100,000 investment in this private placement, the investor will receive $120,000 of common stock 1 year from the date of investment. The price per share will be determined by the market value at the time the common stock will be issued. This correlates to a 20% return on investment. Minimum investment is $25,000. Prior to investing, all investors must verify their accredited status. No offering is made to any person who does not meet the definition of an accredited investor under Rule 501(a). Further information is contained in our private placement memorandum, which should be reviewed in full before making a decision to invest.

Visit our website to participate in THC Therapeutics Private Placement. (http://thctherapeutics.com/)

Comments from Brandon Romanek, Founder & CEO, “Because of my vast experience as a trader, investor and portfolio manager, I have come up with a creative strategy where one can make a potential 20% return on investment. This will be great for THC Therapeutics, our current shareholders and investors in this offering. I am not willing to sell shares at a discount in an offering like this anywhere near our current stock price. Most of these types of offerings are priced below market value. Investors would have to hold for one year and this could present substantial risk to the investor. That structure does not work at all for THC Therapeutics. When a company does that, it makes a statement of what they believe their current stock price should be and that they’re willing to raise money at a significant discount to market. I am now in the process of returning 1.8 Million shares of my stock in THCT back into the company’s treasury. I am doing this to limit any dilution that can occur with this offering. I’d be happy to personally answer any questions regarding this private placement. Please call or email me directly at Brandon@thctherapeutics.com. I would like to thank everyone for believing in my vision and I promise to do whatever it takes to make THC Therapeutics a premier Health and Healing Cannabis company.”

About THC Therapeutics:

THC Therapeutics is a forward-thinking publicly traded health and healing company in the cannabis industry that has "Better Health through the Science of Nature" as their mission statement. The company is dedicated to innovating new methods and refining current industry standards in the cannabis market. THC Therapeutics' plans for future growth include cultivation, dispensing, extractions, edibles, personal wellness centers and flotation therapy. For more information, visit THCTherapeutics.com.

Forward-Looking Statements Disclosure:

This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," "plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.

Phone: 702.602.THCC (8422)

Follow Brandon Romanek on Twitter:

Twitter @BrandonRomanek

Follow THC Therapeutics on Facebook and Twitter:

Twitter @THCTherapeutics

Facebook @THCTherapies

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
14 Aug
PNDORA
  Jeg har løbende adgang til Carnegies analyser af Pandora og har senest i dag modtaget seks slides,..
55
11 Aug
I:DAX
Hej   "Bull markets are born on pessimism, grown on skepticism, mature on optimism and die on euphor..
38
11 Aug
EI
Kære EI Var det muligt at begrænse trompeten og baronen84, til 5 indlæg i døgnet, dels for at højne..
23
16 Aug
BAVA
Kære Bavarian aktionærer jeg har forsøgt at samle lidt informationer sammen dels taget fra ”sodazare..
22
13 Aug
VWS
Godaften allesammen Jeg mener at analytikkernes estimat for Vestas ordre indtag fir indeværende år..
20
17 Aug
 
Hvis du ikke kan tåle -1,5% uden at skulle skrive et indlæg om at gå kontant, er aktiemarkedet for h..
19
15 Aug
VWS
Hej Per.   1) Når et selskab køber aktier bliver de en del af virksomhedens ejendom - de kan derfor ..
15
14 Aug
ONXEO
Jeg vil gerne give et brush up. Mit udgangspunkt er, at jeg har aktier i selskabet og derfor har nog..
15
17 Aug
BABA
Ingen ting i forhold til Goodwrench på uge basis 
14
15 Aug
VWS
Stop nu dig selv menneske. Du har tudet og vrælet op om, hvor elendigt kursen har ageret siden oktob..
14

Alliance Trust PLC : Net Asset Value(s)

17/08/2017 14:10:16
ALLIANCE TRUST PLC                                    At the close of business on Wednesday 16 August 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 769.3p -       including income, 778.7p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding in..

Form 8.3 - Wood Group (John) Plc

17/08/2017 13:46:26
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Kames Capital Plc (b) Owner or contro..

Dimensional Fund Advisors Ltd. : Form 8.3 - Tesco Plc - Ordinary shares

17/08/2017 10:26:28
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Charming Trim and Thinfilm Launch Industry's First Complete Solution for 'Smart' NFC Hang Tags, Enabling Direct Brand-to-Customer Mobile Connections for Apparel and Beyond
2
BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2017
3
Oxford BioMedica plc: INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2017
4
Neura Makes Smart Homes Smarter With Its Artificial Intelligence Solution
5
NN Group reports 2Q17 results

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 August 2017 00:19:22
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170808.1 - EUROWEB2 - 2017-08-18 01:19:22 - 2017-08-18 00:19:22 - 1000 - Website: OKAY